Connecting to SEC EDGAR… PricingSign in
← All filings
Perspective Therapeutics, Inc.CATX · Nov 6, 12:05 PM ET

Melanoma drug shows 75% disease control rate at 3.0 mCi dose

Perspective Therapeutics presented interim Phase 1/2a data for its investigational lapemelanotide zapixetar at the SITC meeting, reporting two partial responses among eight patients at the 3.0 mCi dose and no dose-limiting toxicities across 20 patients.

AI-generated summary, checked against the filing. Can contain errors: read the original filing ↗. Not investment advice.